NCTalks with Claude Wischik: targeting tau to combat Alzheimer’s disease
Jun 13 - 2017 06:29 PM
In this NCTalks podcast, Lauren Pulling, Editor of Neuro Central, is joined by Claude Wischik. A pioneer in tau research, he discovered the tau protein compositional structure of Alzheimer’s tangles and established that it was possible to dissolve these tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors.
“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec
Apr 12 - 2017 01:10 PM
The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed.
Targeting tau protein in Alzheimer's disease
Nov 16 - 2016 11:20 AM
Alzheimer's disease, the most common dementing illness, is a relentlessly progressive and fatal brain disorder that begins approximately 10–15 years before any symptoms manifest.
Regulators Tell Frontotemporal Dementia Community: We Play on Your Team
Apr 26 - 2016 10:52 AM
A meeting convened by the FTD Treatment Study Group offered an assembly of academic and industry scientists, funders, representatives of patient organizations, and caregivers the rare opportunity to collectively pick the brains of senior scientists from the Food and Drug Administration and the European Medicines Agency.
A 30-Year Quest For Alzheimer's Remedy Nears The Finish Line
Mar 18 - 2016 02:44 AM
After decades of researching a treatment for Alzheimer’s, Claude Wischik is set to find out whether his lonely 30-year battle can lead to one of the first real treatments for the memory-destroying brain disorder that afflicts millions worldwide.